Global Hepatitis B Drug Market Research Report 2023

December 2023 | 86 pages | ID: GCD28BBF84BCEN
QYResearch

Abstracts

Treatment for chronic hepatitis B may include: Antiviral medications. Several antiviral medications — including entecavir (Baraclude), tenofovir (Viread), lamivudine (Epivir), adefovir (Hepsera) and telbivudine (Tyzeka) — can help fight the virus and slow its ability to damage your liver.

According to QYResearch’s new survey, global Hepatitis B Drug market is projected to reach US$ 3242.7 million in 2029, increasing from US$ 2157 million in 2022, with the CAGR of 6.0% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hepatitis B Drug market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Hepatitis B Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

• GlaxoSmithKline
• Bristol-Myers Squibb
• Mitsubishi Tanabe Pharma
• Johnson & Johnson
• Roche
• Gilead Sciences
• Merck & Co. Inc.
• Novartis
• AbbVie

Segment by Type

• Entecavir
• Tenofovir
• Lamivudine
• Adefovir
• Telbivudine
• Others

Segment by Application

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Others

By Region

• North America
• United States
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Nordic Countries
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia
• Latin America
• Mexico
• Brazil
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of MEA

The Hepatitis B Drug report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies’ Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies’ Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Market Analysis by Type
  1.2.1 Global Hepatitis B Drug Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
  1.2.2 Entecavir
  1.2.3 Tenofovir
  1.2.4 Lamivudine
  1.2.5 Adefovir
  1.2.6 Telbivudine
  1.2.7 Others
1.3 Market by Application
  1.3.1 Global Hepatitis B Drug Market Growth by Application: 2018 VS 2022 VS 2029
  1.3.2 Hospital Pharmacies
  1.3.3 Retail Pharmacies & Drug Stores
  1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Hepatitis B Drug Market Perspective (2018-2029)
2.2 Hepatitis B Drug Growth Trends by Region
  2.2.1 Global Hepatitis B Drug Market Size by Region: 2018 VS 2022 VS 2029
  2.2.2 Hepatitis B Drug Historic Market Size by Region (2018-2023)
  2.2.3 Hepatitis B Drug Forecasted Market Size by Region (2024-2029)
2.3 Hepatitis B Drug Market Dynamics
  2.3.1 Hepatitis B Drug Industry Trends
  2.3.2 Hepatitis B Drug Market Drivers
  2.3.3 Hepatitis B Drug Market Challenges
  2.3.4 Hepatitis B Drug Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Hepatitis B Drug Players by Revenue
  3.1.1 Global Top Hepatitis B Drug Players by Revenue (2018-2023)
  3.1.2 Global Hepatitis B Drug Revenue Market Share by Players (2018-2023)
3.2 Global Hepatitis B Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Hepatitis B Drug Revenue
3.4 Global Hepatitis B Drug Market Concentration Ratio
  3.4.1 Global Hepatitis B Drug Market Concentration Ratio (CR5 and HHI)
  3.4.2 Global Top 10 and Top 5 Companies by Hepatitis B Drug Revenue in 2022
3.5 Hepatitis B Drug Key Players Head office and Area Served
3.6 Key Players Hepatitis B Drug Product Solution and Service
3.7 Date of Enter into Hepatitis B Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 HEPATITIS B DRUG BREAKDOWN DATA BY TYPE

4.1 Global Hepatitis B Drug Historic Market Size by Type (2018-2023)
4.2 Global Hepatitis B Drug Forecasted Market Size by Type (2024-2029)

5 HEPATITIS B DRUG BREAKDOWN DATA BY APPLICATION

5.1 Global Hepatitis B Drug Historic Market Size by Application (2018-2023)
5.2 Global Hepatitis B Drug Forecasted Market Size by Application (2024-2029)

6 NORTH AMERICA

6.1 North America Hepatitis B Drug Market Size (2018-2029)
6.2 North America Hepatitis B Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Hepatitis B Drug Market Size by Country (2018-2023)
6.4 North America Hepatitis B Drug Market Size by Country (2024-2029)
6.5 United States
6.6 Canada

7 EUROPE

7.1 Europe Hepatitis B Drug Market Size (2018-2029)
7.2 Europe Hepatitis B Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Hepatitis B Drug Market Size by Country (2018-2023)
7.4 Europe Hepatitis B Drug Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries

8 ASIA-PACIFIC

8.1 Asia-Pacific Hepatitis B Drug Market Size (2018-2029)
8.2 Asia-Pacific Hepatitis B Drug Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Hepatitis B Drug Market Size by Region (2018-2023)
8.4 Asia-Pacific Hepatitis B Drug Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia

9 LATIN AMERICA

9.1 Latin America Hepatitis B Drug Market Size (2018-2029)
9.2 Latin America Hepatitis B Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Hepatitis B Drug Market Size by Country (2018-2023)
9.4 Latin America Hepatitis B Drug Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Hepatitis B Drug Market Size (2018-2029)
10.2 Middle East & Africa Hepatitis B Drug Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Hepatitis B Drug Market Size by Country (2018-2023)
10.4 Middle East & Africa Hepatitis B Drug Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE

11 KEY PLAYERS PROFILES

11.1 GlaxoSmithKline
  11.1.1 GlaxoSmithKline Company Detail
  11.1.2 GlaxoSmithKline Business Overview
  11.1.3 GlaxoSmithKline Hepatitis B Drug Introduction
  11.1.4 GlaxoSmithKline Revenue in Hepatitis B Drug Business (2018-2023)
  11.1.5 GlaxoSmithKline Recent Development
11.2 Bristol-Myers Squibb
  11.2.1 Bristol-Myers Squibb Company Detail
  11.2.2 Bristol-Myers Squibb Business Overview
  11.2.3 Bristol-Myers Squibb Hepatitis B Drug Introduction
  11.2.4 Bristol-Myers Squibb Revenue in Hepatitis B Drug Business (2018-2023)
  11.2.5 Bristol-Myers Squibb Recent Development
11.3 Mitsubishi Tanabe Pharma
  11.3.1 Mitsubishi Tanabe Pharma Company Detail
  11.3.2 Mitsubishi Tanabe Pharma Business Overview
  11.3.3 Mitsubishi Tanabe Pharma Hepatitis B Drug Introduction
  11.3.4 Mitsubishi Tanabe Pharma Revenue in Hepatitis B Drug Business (2018-2023)
  11.3.5 Mitsubishi Tanabe Pharma Recent Development
11.4 Johnson & Johnson
  11.4.1 Johnson & Johnson Company Detail
  11.4.2 Johnson & Johnson Business Overview
  11.4.3 Johnson & Johnson Hepatitis B Drug Introduction
  11.4.4 Johnson & Johnson Revenue in Hepatitis B Drug Business (2018-2023)
  11.4.5 Johnson & Johnson Recent Development
11.5 Roche
  11.5.1 Roche Company Detail
  11.5.2 Roche Business Overview
  11.5.3 Roche Hepatitis B Drug Introduction
  11.5.4 Roche Revenue in Hepatitis B Drug Business (2018-2023)
  11.5.5 Roche Recent Development
11.6 Gilead Sciences
  11.6.1 Gilead Sciences Company Detail
  11.6.2 Gilead Sciences Business Overview
  11.6.3 Gilead Sciences Hepatitis B Drug Introduction
  11.6.4 Gilead Sciences Revenue in Hepatitis B Drug Business (2018-2023)
  11.6.5 Gilead Sciences Recent Development
11.7 Merck & Co. Inc.
  11.7.1 Merck & Co. Inc. Company Detail
  11.7.2 Merck & Co. Inc. Business Overview
  11.7.3 Merck & Co. Inc. Hepatitis B Drug Introduction
  11.7.4 Merck & Co. Inc. Revenue in Hepatitis B Drug Business (2018-2023)
  11.7.5 Merck & Co. Inc. Recent Development
11.8 Novartis
  11.8.1 Novartis Company Detail
  11.8.2 Novartis Business Overview
  11.8.3 Novartis Hepatitis B Drug Introduction
  11.8.4 Novartis Revenue in Hepatitis B Drug Business (2018-2023)
  11.8.5 Novartis Recent Development
11.9 AbbVie
  11.9.1 AbbVie Company Detail
  11.9.2 AbbVie Business Overview
  11.9.3 AbbVie Hepatitis B Drug Introduction
  11.9.4 AbbVie Revenue in Hepatitis B Drug Business (2018-2023)
  11.9.5 AbbVie Recent Development

12 ANALYST'S VIEWPOINTS/CONCLUSIONS


13 APPENDIX

13.1 Research Methodology
  13.1.1 Methodology/Research Approach
  13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Hepatitis B Drug Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Entecavir
Table 3. Key Players of Tenofovir
Table 4. Key Players of Lamivudine
Table 5. Key Players of Adefovir
Table 6. Key Players of Telbivudine
Table 7. Key Players of Others
Table 8. Global Hepatitis B Drug Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Hepatitis B Drug Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 10. Global Hepatitis B Drug Market Size by Region (2018-2023) & (US$ Million)
Table 11. Global Hepatitis B Drug Market Share by Region (2018-2023)
Table 12. Global Hepatitis B Drug Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 13. Global Hepatitis B Drug Market Share by Region (2024-2029)
Table 14. Hepatitis B Drug Market Trends
Table 15. Hepatitis B Drug Market Drivers
Table 16. Hepatitis B Drug Market Challenges
Table 17. Hepatitis B Drug Market Restraints
Table 18. Global Hepatitis B Drug Revenue by Players (2018-2023) & (US$ Million)
Table 19. Global Hepatitis B Drug Market Share by Players (2018-2023)
Table 20. Global Top Hepatitis B Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Drug as of 2022)
Table 21. Ranking of Global Top Hepatitis B Drug Companies by Revenue (US$ Million) in 2022
Table 22. Global 5 Largest Players Market Share by Hepatitis B Drug Revenue (CR5 and HHI) & (2018-2023)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Hepatitis B Drug Product Solution and Service
Table 25. Date of Enter into Hepatitis B Drug Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Hepatitis B Drug Market Size by Type (2018-2023) & (US$ Million)
Table 28. Global Hepatitis B Drug Revenue Market Share by Type (2018-2023)
Table 29. Global Hepatitis B Drug Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 30. Global Hepatitis B Drug Revenue Market Share by Type (2024-2029)
Table 31. Global Hepatitis B Drug Market Size by Application (2018-2023) & (US$ Million)
Table 32. Global Hepatitis B Drug Revenue Market Share by Application (2018-2023)
Table 33. Global Hepatitis B Drug Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 34. Global Hepatitis B Drug Revenue Market Share by Application (2024-2029)
Table 35. North America Hepatitis B Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 36. North America Hepatitis B Drug Market Size by Country (2018-2023) & (US$ Million)
Table 37. North America Hepatitis B Drug Market Size by Country (2024-2029) & (US$ Million)
Table 38. Europe Hepatitis B Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. Europe Hepatitis B Drug Market Size by Country (2018-2023) & (US$ Million)
Table 40. Europe Hepatitis B Drug Market Size by Country (2024-2029) & (US$ Million)
Table 41. Asia-Pacific Hepatitis B Drug Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 42. Asia-Pacific Hepatitis B Drug Market Size by Region (2018-2023) & (US$ Million)
Table 43. Asia-Pacific Hepatitis B Drug Market Size by Region (2024-2029) & (US$ Million)
Table 44. Latin America Hepatitis B Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 45. Latin America Hepatitis B Drug Market Size by Country (2018-2023) & (US$ Million)
Table 46. Latin America Hepatitis B Drug Market Size by Country (2024-2029) & (US$ Million)
Table 47. Middle East & Africa Hepatitis B Drug Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 48. Middle East & Africa Hepatitis B Drug Market Size by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Hepatitis B Drug Market Size by Country (2024-2029) & (US$ Million)
Table 50. GlaxoSmithKline Company Detail
Table 51. GlaxoSmithKline Business Overview
Table 52. GlaxoSmithKline Hepatitis B Drug Product
Table 53. GlaxoSmithKline Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 54. GlaxoSmithKline Recent Development
Table 55. Bristol-Myers Squibb Company Detail
Table 56. Bristol-Myers Squibb Business Overview
Table 57. Bristol-Myers Squibb Hepatitis B Drug Product
Table 58. Bristol-Myers Squibb Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 59. Bristol-Myers Squibb Recent Development
Table 60. Mitsubishi Tanabe Pharma Company Detail
Table 61. Mitsubishi Tanabe Pharma Business Overview
Table 62. Mitsubishi Tanabe Pharma Hepatitis B Drug Product
Table 63. Mitsubishi Tanabe Pharma Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 64. Mitsubishi Tanabe Pharma Recent Development
Table 65. Johnson & Johnson Company Detail
Table 66. Johnson & Johnson Business Overview
Table 67. Johnson & Johnson Hepatitis B Drug Product
Table 68. Johnson & Johnson Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 69. Johnson & Johnson Recent Development
Table 70. Roche Company Detail
Table 71. Roche Business Overview
Table 72. Roche Hepatitis B Drug Product
Table 73. Roche Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 74. Roche Recent Development
Table 75. Gilead Sciences Company Detail
Table 76. Gilead Sciences Business Overview
Table 77. Gilead Sciences Hepatitis B Drug Product
Table 78. Gilead Sciences Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 79. Gilead Sciences Recent Development
Table 80. Merck & Co. Inc. Company Detail
Table 81. Merck & Co. Inc. Business Overview
Table 82. Merck & Co. Inc. Hepatitis B Drug Product
Table 83. Merck & Co. Inc. Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 84. Merck & Co. Inc. Recent Development
Table 85. Novartis Company Detail
Table 86. Novartis Business Overview
Table 87. Novartis Hepatitis B Drug Product
Table 88. Novartis Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 89. Novartis Recent Development
Table 90. AbbVie Company Detail
Table 91. AbbVie Business Overview
Table 92. AbbVie Hepatitis B Drug Product
Table 93. AbbVie Revenue in Hepatitis B Drug Business (2018-2023) & (US$ Million)
Table 94. AbbVie Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Hepatitis B Drug Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Hepatitis B Drug Market Share by Type: 2022 VS 2029
Figure 3. Entecavir Features
Figure 4. Tenofovir Features
Figure 5. Lamivudine Features
Figure 6. Adefovir Features
Figure 7. Telbivudine Features
Figure 8. Others Features
Figure 9. Global Hepatitis B Drug Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 10. Global Hepatitis B Drug Market Share by Application: 2022 VS 2029
Figure 11. Hospital Pharmacies Case Studies
Figure 12. Retail Pharmacies & Drug Stores Case Studies
Figure 13. Others Case Studies
Figure 14. Hepatitis B Drug Report Years Considered
Figure 15. Global Hepatitis B Drug Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Hepatitis B Drug Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Hepatitis B Drug Market Share by Region: 2022 VS 2029
Figure 18. Global Hepatitis B Drug Market Share by Players in 2022
Figure 19. Global Top Hepatitis B Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hepatitis B Drug as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Hepatitis B Drug Revenue in 2022
Figure 21. North America Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. North America Hepatitis B Drug Market Share by Country (2018-2029)
Figure 23. United States Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Hepatitis B Drug Market Share by Country (2018-2029)
Figure 27. Germany Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Hepatitis B Drug Market Share by Region (2018-2029)
Figure 35. China Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Japan Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. South Korea Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Southeast Asia Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. India Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Australia Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Hepatitis B Drug Market Share by Country (2018-2029)
Figure 43. Mexico Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Brazil Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Hepatitis B Drug Market Share by Country (2018-2029)
Figure 47. Turkey Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Saudi Arabia Hepatitis B Drug Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. GlaxoSmithKline Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 50. Bristol-Myers Squibb Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 51. Mitsubishi Tanabe Pharma Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 52. Johnson & Johnson Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 53. Roche Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 54. Gilead Sciences Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 55. Merck & Co. Inc. Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 56. Novartis Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 57. AbbVie Revenue Growth Rate in Hepatitis B Drug Business (2018-2023)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed